Dermal fillers are the second most popular cosmetic medical treatment worldwide, and the vast majority of injections are uneventful. Swelling, bruising, and mild tenderness resolve within days. But complications range along a spectrum from trivial to sight-threatening, and the window for intervening on the serious ones can be narrow. A 2026 retrospective study of filler complications presenting to a university dermatology department found that over half of the complications involved either uncertified products or injections by non-medical practitioners.
This article is a patient-facing reference: what to expect after filler, what is normal, what is not, and what to ask your provider before treatment.
The complication spectrum, by timing
Complications are generally grouped by when they appear:
Immediate (minutes to hours)
- Bruising and swelling. The most common side effects. Bruising results from needle injury to small vessels. Swelling is a normal inflammatory response. Both typically peak within 24–48 hours and resolve within 1–2 weeks. Arnica and cold compresses may help.
- Redness and tenderness. Expected at injection sites. Should steadily improve, not worsen.
- Vascular occlusion. This is the one true emergency. Filler enters or compresses a blood vessel, cutting off blood supply to tissue. Signs include sudden severe pain, skin blanching (turning white), a dusky or mottled purple discoloration, delayed capillary refill (press the skin and it does not turn pink again within seconds), and tissue that feels cool to the touch. This can progress to skin necrosis if untreated. Vascular occlusion near the eye can cause blindness.
Early (days to weeks)
- Infection. Redness, warmth, swelling, and pain that worsen rather than improve, sometimes with fever. Bacterial infection can develop into an abscess. Herpes simplex reactivation is also possible in perioral filler.
- Tyndall effect. A bluish-gray discoloration under the skin, most visible in areas with thin skin such as the tear troughs. It occurs when hyaluronic acid (HA) filler is placed too superficially. Light scattering through the filler particles creates the blue hue. It is not dangerous but is cosmetically bothersome and correctable with hyaluronidase.
- Nodules and lumps. Small palpable bumps at the injection site. Some are normal filler settling and massage resolves them within days. Persistent or enlarging nodules need evaluation.
- Allergic or hypersensitivity reactions. Redness, itching, swelling, or hives beyond the injection site. True IgE-mediated anaphylaxis from HA fillers is rare but has been reported.
Late (weeks to years)
- Biofilm. A chronic low-grade bacterial infection embedded in a protective matrix around the filler. Signs include recurrent swelling, persistent or migrating nodules, and intermittent redness, often triggered by dental work, illness, or other immune stressors. Biofilms are difficult to culture and may not respond to antibiotics alone — hyaluronidase to remove the filler and prolonged antibiotic therapy are typically needed.
- Delayed-onset nodules and granulomas. Inflammatory nodules appearing months or years after injection. The 2026 university hospital study found that approximately one-third of patients with filler complications presented with chronic immune reactions, including biofilm and foreign-body granulomas. These can be triggered by infections, dental procedures, or immune system changes.
- Filler migration. Filler shifts from the injection site to adjacent tissue, creating visible fullness or distortion in an unintended area. A 2023 narrative review documented migration as a recognized phenomenon with all filler types, not just HA.
The emergencies: vascular occlusion and blindness
Vascular occlusion is the most feared acute complication of dermal fillers. A large retrospective study by Alam et al. (2021), involving 370 dermatologists over a 10-year period, estimated the incidence at approximately 1 in 5,000 syringes injected — encompassing all vascular occlusion events from transient blanching to tissue necrosis. The rate of impending skin necrosis specifically is lower, estimated at 0.001%–0.009% of procedures. The American Society of Plastic Surgeons states that in rare cases, filler "may accidentally be injected into your blood vessels instead of under your skin," which "can block blood flow" and result in "skin loss or wounds" or — if the eye is affected — loss of eyesight. For a detailed discussion of mechanism, high-risk zones, and treatment protocols, see our guide to filler vascular occlusion.
Warning signs of vascular occlusion
The Rhode Island Eye Institute describes the key red flags:
- Skin color changes. Blanching (sudden whitening) lasting more than a few minutes, a dusky or mottled purple net-like pattern (livedo reticularis), or skin turning grey.
- Pain out of proportion. Sharp, intense pain that feels distinctly different from normal injection discomfort, and that gets worse over the following minutes rather than fading.
- Pain radiating to the eye, forehead, or nose. Especially after filler in the glabella (between the brows), tear troughs, nose, or temples.
- Delayed capillary refill. Press the skin and it stays pale instead of returning to its normal color within 2 seconds.
What should happen
If the filler is hyaluronic acid, high-dose hyaluronidase should be injected promptly into the area of occlusion and its periphery. The ASDS Task Force recommends immediate high-dose hyaluronidase as a strong recommendation (moderate certainty evidence). Massage, warm compresses, and vasodilators may be used alongside. For non-HA fillers (CaHA, PLLA, PMMA), treatment options are more limited — sodium thiosulfate has been used off-label for calcium hydroxylapatite.
If you experience these signs, contact your injector immediately or go to the nearest emergency department. Time matters.
Blindness risk
Blindness from filler occurs when material enters an artery that communicates with the ophthalmic or central retinal artery. The areas of highest risk are the nose (dorsum and alar groove), glabella, forehead, and periorbital region. A global review found that blindness occurred in approximately 0.94% of reported filler complications involving the nose, supraorbital area, and cheek. For a comprehensive discussion of mechanism, danger zones, and prevention, see our guide to filler blindness risk.
Management of filler-induced vision loss remains controversial and outcomes are often poor. Retrobulbar hyaluronidase injection, anterior chamber paracentesis, ocular massage, and hyperbaric oxygen have all been attempted with variable results. Prevention — through anatomical knowledge, appropriate injection technique, and avoiding high-risk zones with high-pressure boluses — is far more effective than any treatment after the event.
What to do at each stage
Immediately after treatment (first 24–48 hours)
What is normal:
- Mild to moderate swelling, especially in the lips and under-eyes.
- Bruising that appears over the first day and gradually fades.
- Mild tenderness at injection sites.
- Slight redness.
What is not normal — call your injector or seek emergency care:
- Sudden severe pain that worsens.
- Skin turning white, grey, mottled, or dusky.
- Pain radiating to the eye, forehead, or nose.
- One-sided facial pain with skin color changes.
- Vision changes (blurriness, double vision, loss of vision).
Days 1–7
What is normal:
- Bruising continues to fade (may go through yellow/green phase).
- Swelling gradually decreases. Some asymmetry is common as swelling resolves unevenly.
- Small lumps soften with gentle massage (if your provider has recommended it).
What is not normal — contact your injector:
- Redness, warmth, or swelling that worsens after the first 48 hours.
- Fever or feeling unwell.
- Pain that increases rather than decreases.
- Visible bluish discoloration (Tyndall effect).
- Hard, enlarging, or tender nodules.
Weeks to months later
What is not normal — schedule a follow-up:
- New nodules appearing weeks or months after treatment.
- Recurrent episodes of swelling, especially if triggered by dental work or illness.
- Visible asymmetry, distortion, or fullness in areas away from the injection site (possible migration).
Red flags when choosing a provider
The 2026 retrospective study found that in over half of the complicated cases seen at a university dermatology department, the injections had been performed by cosmeticians, non-medical practitioners, or individuals of unknown qualification, and more than half of the products involved were either uncertified or of unknown origin. The FDA has also raised concerns about counterfeit filler products entering the supply chain.
Before you book, verify that:
- The injector is a licensed medical professional (board-certified dermatologist, plastic surgeon, facial plastic surgeon, or a nurse practitioner/physician assistant working under direct physician supervision).
- They use FDA-approved products and can show you the sealed packaging.
- They have a hyaluronidase protocol for managing vascular occlusion on site.
- They take a full medical history including autoimmune conditions, prior fillers, blood thinners, cold sore history, and allergies.
- They discuss the specific risks for the area being treated, not just general side effects.
What filler cannot do
No filler lasts forever. HA fillers typically last 6–18 months depending on the product, the area, and individual metabolism. Biostimulators (Sculptra, Radiesse) last longer but are not reversible. If you are building toward a future surgical procedure — a facelift, blepharoplasty, or rhinoplasty — discuss how accumulated filler might affect the surgical plan. Some surgeons recommend dissolving filler several weeks before surgery to restore natural anatomy.
Sources
- Nguyen L, Herberger K, et al. "Complications of Dermal Injectables — A Retrospective Study." Journal of Cosmetic Dermatology, 2026. https://pubmed.ncbi.nlm.nih.gov/41555790
- Alam M, et al. "Rates of Vascular Occlusion Associated With Using Needles vs Cannulas for Filler Injection." JAMA Dermatology, 2021;157(2):174–180.
- American Society of Plastic Surgeons. "Dermal Fillers Risks and Safety." plasticsurgery.org, 2026. https://www.plasticsurgery.org/cosmetic-procedures/dermal-fillers/safety
- Fazel-Zarandi M, et al. "Hyaluronidase for Dermal Filler Complications: Review of Applications and Dosage Recommendations." JMIR Dermatology, 2024. https://derma.jmir.org/2024/1/e50403
- ASDS Task Force. "Preventing and Treating Adverse Events of Injectable Fillers: Evidence-Based Recommendations from the ASDS Task Force." American Society for Dermatologic Surgery. https://www.asds.net/Portals/0/PDF/asdsa/Preventing%20and%20Treating%20Adverse%20Events%20of%20Injectable%20Fillers%20Evidence-Based%20Recs%20From%20ASDS%20Task%20Force%20Article.pdf
- U.S. Food and Drug Administration. "Dermal Fillers — Executive Summary." FDA General Issues Panel Meeting, 2025. https://www.fda.gov/media/188185/download
- Beleznay K, Humphrey S, et al. "Update on Blindness from Filler: Review of Prognostic Factors and Management." Aesthetic Surgery Journal, 2024;44(10):1091–1106.
- Wollina U, Goldman A. "Filler Migration After Facial Injection — A Narrative Review." Cosmetics, 2023;10(4):115.
- Adverse Effects Associated with Dermal Filler Treatments: Part II — Vascular Complication. Diagnostics, 2024;14(14):1555. https://www.mdpi.com/2075-4418/14/14/1555
